Kraj: Malezja
Język: angielski
Źródło: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
NEVIRAPINE HEMIHYDRATE
UNIMED SDN BHD
NEVIRAPINE HEMIHYDRATE
240 ml; 100 ml
Aurobindo Pharma Limited (Unit III),
(For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory) NEVIREX (NEVIRAPINE ORAL SUSPENSION 50MG/5ML) (Nevirapine 50mg/5ml) COMPOSITION: Each 5 ml contains: Nevirapine USP as Nevirapine hemihydrate 50mg/5ml Methyl paraben as preservative 9 mg Propylparaben as preservative 1.2 mg DOSAGE FORM: Powder for oral suspension DESCRIPTION: White to off white homogenous suspension. PHARMACODYNAMICS & PHARMACOKINETICS: PHARMACODYNAMICS: PHARMACOTHERAPEUTIC GROUP: antiviral agent, ATC code J05A G01. _MECHANISM OF ACTION _ Nevirapine is a NNRTI of HIV-1. Nevirapine binds directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. HIV-2 reverse transcriptase and eukaryotic DNA polymerases (such as human DNA polymerases α, β, γ, or δ) are not inhibited by nevirapine. RESISTANCE HIV isolates with reduced susceptibility (100 to 250-fold) to nevirapine emerge in vitro. Phenotypic and genotypic changes occur in HIV isolates from patients treated with Nevirapine or Nevirapine + zidovudine over one to 12 weeks. By week 8 of Nevirapine monotherapy, 100 % of the patients tested had HIV isolates with a >100-fold decrease in susceptibility to nevirapine, regardless of dose. Nevirapine + zidovudine combination therapy did not alter the emergence rate of nevirapine-resistant virus. Genotypic and phenotypic resistance was examined for patients receiving Nevirapine in triple and double therapy drug combination therapy, and in the non- Nevirapine comparative group from the INCAS study. Antiretroviral naive subjects with CD4 cells counts of 200-600/mm3 were treated with either Nevirapine + zidovudine (n = 46), zidovudine + didanosine (n = 51) or Nevirapine + zidovudine + didanosine (n = 51) and followed for 52 weeks or longer on therapy. Virologic evaluations were performed at baseline, six months and 12 months. The phenoty Przeczytaj cały dokument